NCT01522872View on ClinicalTrials.gov

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2017

Conditions
Multiple Myeloma
Interventions
DRUG

TH-302

DRUG

TH-302 and Dexamethasone

DRUG

TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib

DRUG

TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide

Trial Locations (10)

12208

New York Oncology Hematology, Albany

12534

New York Oncology Hematology, Hudson

33612

Moffitt Cancer Center, Tampa

38120

The West Clinic, Memphis

38671

The West Clinic, Southaven

93940

Pacific Cancer Care, Monterey

04074

Maine Center for Cancer Medicine, Scarborough

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Threshold Pharmaceuticals

INDUSTRY